Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Christoph M Rueegger, Peter G Davis, Jeanie L Cheong
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | WILEY | Published : 2018
BACKGROUND: Hypoxic-ischaemic encephalopathy (HIE) is a serious birth complication affecting term and late preterm newborns. Although therapeutic hypothermia (cooling) has been shown to be an effective therapy for neonatal HIE, many cooled infants have poor long-term neurodevelopmental outcomes. In animal models of neonatal encephalopathy, inhaled xenon combined with cooling has been shown to offer better neuroprotection than cooling alone. OBJECTIVES: To determine the effects of xenon as an adjuvant to therapeutic hypothermia on mortality and neurodevelopmental morbidity, and to ascertain clinically important side effects of xenon plus therapeutic hypothermia in newborn infants with HIE. To..View full abstract
Awarded by Swiss National Science Foundation, Switzerland
Internal sourcesThe Royal Women's Hospital, Melbourne, Australia.External sourcesThe Swiss National Science Foundation (Early Postdoc Mobility Fellowship P2ZHP3.161749 to CMR), Switzerland.Vermont Oxford Network, USA.Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a worldwide collaboration of health professionals dedicated to providing evidence-based care of the highest quality for newborn infants and their families.